Further investigations revealed that in the pancreatic adenocarcinoma, TFAP2A inhibits cell cycle regulators, such as decreased cyclin dependent kinase 4 (CDK-4), cyclin dependent kinase 6 (CDK-6), cyclin-G1 and CDKN1C/P57, while increasing P27 (also known as CDKN1B, Cyclin Dependent Kinase Inhibitor 1B) by binding to the P27 promoter to activate its expression by which cell cycle arrests [12, 87]. Here, CDKN1B is linked to pancreatic adenocarcinoma.